LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BioVendor Group Introduces Groundbreaking Immunological Biomarker

By LabMedica International staff writers
Posted on 13 Nov 2024
Print article
Image: BioVendor Group is showcasing its impressive diagnostic innovations at MEDICA 2024 (Photo courtesy of BioVendor)
Image: BioVendor Group is showcasing its impressive diagnostic innovations at MEDICA 2024 (Photo courtesy of BioVendor)

At this year’s MEDICA, BioVendor Group (Brno, Czech Republic) is showcasing its impressive diagnostic innovations, from CLIA advancements to the groundbreaking MxA biomarker, which plays a key role in distinguishing between bacterial and viral infections.

BioVendor Group is fitting all group companies into a shared exhibition space at MEDICA 2024 and creating a welcoming environment for hundreds of meetings with new and existing business partners, customers, and suppliers. Visitors to the shared BioVendor Group booth can learn about several other product news and innovations from the companies BioVendor Research & Diagnostic Products, TestLine Clinical Diagnostics s.r.o., ViennaLab Diagnostics, DIAsource ImmunoAssays S.A. and BioVendor MDx. The main "drivers" are again the key projects CLIA, MBA, and NGS, developed in synergy by the various companies of the BioVendor Group. BioVendor is introducing brand-new micro-array kits from TestLine Clinical Diagnostics for the diagnosis of liver and gastrointestinal autoimmune diseases. Also featuring at the show is BioVendor MDx’s NGS fastGEN technology which offers rapid and accurate genetic analysis, enabling efficient cancer diagnostics. BioVendor MDx’s fastGEN BCR::ABL1 cancer kit specifically detects fusion genes associated with leukemia, supporting early diagnosis and treatment management. In addition to these innovations, visitors can also learn more about BioVendor MDx’s bioinformatics solution GENOVESA which is designed for seamless data interpretation and reporting.

DIAsource is announcing the addition of a new rapid test (POCT) and its respective reader to the company’s portfolio. These products complete the company’s panel with additional technologies and interesting parameters in the fields of women’s health, tumor markers, drugs of abuse, infectious diseases, cardiac markers. DIAsource is also launching a series of new antibodies in the fields of Alzheimer's disease, cardiac markers, diabetes and fertility. These antibodies have proven to be reliable raw materials in the manufacturing of immunoassays such as CLIA, ELISA, FIA, and POCT. BioVendor RnD is showcasing its extensive portfolio of ELISA kits for both research and diagnostic applications. In addition to its high-quality ELISA kits, the company is highlighting its high-purity proteins and a broad range of antibodies. BioVendor RnD is also presenting the MxA Point-of-Care-Test designed for the rapid differentiation between bacterial and viral infections. Visitors to the shared BioVendor Group booth can also learn about ViennaLab’s upcoming SMA RealFast Assay, comprehensive OncNGS (liquid biopsy (cfDNA) NGS solution), 16S Microbiome + ITS NGS Assay.

Related Links:
BioVendor Group 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.